Product Details

These film-coated tablets meet British Pharmacopoeia standards, supporting hormone therapy for advanced prostate cancer. Oncologists prescribe this combination for patients with metastatic castration-resistant prostate cancer, typically alongside ongoing androgen deprivation therapy.

The tablets combine:

• Abiraterone Acetate BP (250 mg) — a CYP17 inhibitor that blocks androgen production in the testes, adrenal glands, and tumor tissue, reducing the hormonal drive behind prostate cancer growth
• Prednisolone BP (5 mg) — a corticosteroid that offsets the hormonal side effects of Abiraterone therapy and helps maintain normal cortisol levels

Together, these two agents work as a coordinated regimen rather than independent treatments. As a result, VERABIR-P supports sustained androgen suppression while managing the corticosteroid balance Abiraterone therapy requires. Because of this pairing, oncology specialists prescribe it as part of a broader prostate cancer management plan, typically in hospital and specialist outpatient settings.

Key Features

• Meets BP (British Pharmacopoeia) standards for consistent quality
• Pairs a CYP17 inhibitor with a corticosteroid in one coordinated regimen
• Delivers accurate, validated dosing in every tablet batch
• Suits oncology clinic, hospital, and specialist institutional supply
• Follows GMP-compliant manufacturing processes
• Requires reading the package insert before use